A Multicenter Phase II Trial of Ruxolitinib for Treatment of Corticosteroid Refractory Sclerotic Chronic Graft-Versus-Host Disease
The use of ruxolitinib was associated with relatively high rates of skin/joint responses and overall cGVHD responses, improvement in patient-reported outcomes, low NRM, and high FFS in patients with refractory sclerotic cGVHD. Ruxolitinib offers an effective treatment option for refractory sclerotic cGVHD.
Authors
- Stephanie J. Lee (ORCID: https://orcid.org/0000-0003-2600-6390)
- Hannah Choe (ORCID: https://orcid.org/0000-0002-2849-2989)
- Lynette M. Smith (ORCID: https://orcid.org/0000-0002-0836-9932)
- Lori J. Maness
- Betty K. Hamilton (ORCID: https://orcid.org/0000-0003-1252-6539)
- Ram I. Mahato (ORCID: https://orcid.org/0000-0003-3588-0434)
- Vijaya Raj Bhatt (ORCID: https://orcid.org/0000-0003-2513-0533)
- Taiga Nishihori (ORCID: https://orcid.org/0000-0002-2621-7924)
- Valerie Shostrom (ORCID: https://orcid.org/0000-0001-8125-8764)
- Krishna Gundabolu (ORCID: https://orcid.org/0000-0003-4206-7468)
- Virender Kumar (ORCID: https://orcid.org/0000-0001-5353-5656)
Institutions
- Cleveland Clinic (US)
- University of Washington (US)
- Moffitt Cancer Center (US)
- Fred Hutch Cancer Center (US)
- The Ohio State University (US)
- University of Nebraska Medical Center (US)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2024-08-16
- DOI
- https://doi.org/10.1200/jco.24.00205
- Citations
- 12
- Primary Topic
- Hematopoietic Stem Cell Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 5.45
Funders
- Amgen
- Pfizer
- AstraZeneca
- Sanofi
- University of Nebraska Medical Center
- CSL Behring
- MEI Pharma
- Incyte
- Syndax Pharmaceuticals
- National Institutes of Health
- National Cancer Institute
- National Institute of General Medical Sciences